Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AMG 160 + Enzalutamide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AMG 160 | HLE-BiTE AMG 160|AMG-160|AMG160|Acapatamab | PSMA Antibody 16 | AMG 160 is a bi-specific T-cell engager (BiTE) antibody that binds to PSMA and CD3, potentially resulting in enhanced T-cell response and antitumor activity against PSMA-expressing tumor cells (PMID: 33504551). | |
Enzalutamide | Xtandi | MDV3100|ASP9785 | Hormone - Anti-androgens 39 | Xtandi (enzalutamide) is a second-generation small molecule androgen receptor (AR) inhibitor that inhibits AR signaling, thereby resulting in decreased tumor growth (PMID: 24009414, PMID: 25945058). Xtandi (enzalutamide) is FDA approved for use in patients with castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04631601 | Phase I | AMG 160 + AMG 404 AMG 160 + Enzalutamide Abiraterone + AMG 160 AMG 404 | Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) | Active, not recruiting | USA | ESP | 4 |